194 related articles for article (PubMed ID: 32003597)
1. Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease.
Chiloff DM; de Almeida DC; Dalboni MA; Canziani ME; George SK; Morsi AM; El-Akabawy N; Porada CD; Durao MS; Zarjou A; Almeida-Porada G; Goes MA
Am J Physiol Renal Physiol; 2020 Apr; 318(4):F861-F869. PubMed ID: 32003597
[TBL] [Abstract][Full Text] [Related]
2. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
Ingrasciotta Y; Lacava V; Marcianò I; Giorgianni F; Tripepi G; D' Arrigo G; Chinellato A; Ugo Tari D; Santoro D; Trifirò G
BMC Nephrol; 2019 Sep; 20(1):359. PubMed ID: 31521117
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
Kato H; Nangaku M; Hirakata H; Wada T; Hayashi T; Sato H; Yamazaki Y; Masaki T; Kagimura T; Yamamoto H; Hase H; Kamouchi M; Imai E; Mizuno K; Iwasaki M; Akizawa T; Tsubakihara Y; Maruyama S; Narita I
Clin Exp Nephrol; 2018 Feb; 22(1):78-84. PubMed ID: 28660446
[TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
5. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.
Tsuruya K; Yoshida H; Suehiro T; Fujisaki K; Masutani K; Kitazono T
Ren Fail; 2016; 38(3):390-6. PubMed ID: 26822074
[TBL] [Abstract][Full Text] [Related]
6. Renal prognoses by different target hemoglobin levels achieved by epoetin beta pegol dosing to chronic kidney disease patients with hyporesponsive anemia to erythropoiesis-stimulating agent: a multicenter open-label randomized controlled study.
Tsuruya K; Hayashi T; Yamamoto H; Hase H; Nishi S; Yamagata K; Nangaku M; Wada T; Uemura Y; Ohashi Y; Hirakata H;
Clin Exp Nephrol; 2021 May; 25(5):456-466. PubMed ID: 33411115
[TBL] [Abstract][Full Text] [Related]
7. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
[TBL] [Abstract][Full Text] [Related]
8. Serum Soluble-Fas, Inflammation, and Anemia in Acute Kidney Injury.
Góes MA; Iizuka IJ; Quinto BM; Dalboni MA; Monte JC; Santos BC; Dos Santos OFP; Pereira VG; Durão MS; Batista MC; Cendoroglo M
Artif Organs; 2018 Sep; 42(9):E283-E289. PubMed ID: 23566289
[TBL] [Abstract][Full Text] [Related]
9. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
[TBL] [Abstract][Full Text] [Related]
10. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
Koulouridis I; Alfayez M; Trikalinos TA; Balk EM; Jaber BL
Am J Kidney Dis; 2013 Jan; 61(1):44-56. PubMed ID: 22921639
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
[TBL] [Abstract][Full Text] [Related]
12. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
13. Serum-soluble Fas and serum levels of erythropoietin in chronic kidney disease.
Góes MA; Dalboni MA; Manfredi SR; Cendoroglo MS; Batista MC; Canziani ME; Balakrishnan VS; Pereira BJ; Draibe SA; Cendoroglo M
Clin Nephrol; 2010 Jan; 73(1):7-13. PubMed ID: 20040346
[TBL] [Abstract][Full Text] [Related]
14. Iron Metabolism in Chronic Kidney Disease Patients.
Honda H; Hosaka N; Ganz T; Shibata T
Contrib Nephrol; 2019; 198():103-111. PubMed ID: 30991401
[TBL] [Abstract][Full Text] [Related]
15. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.
Seliger S; Fox KM; Gandra SR; Bradbury B; Hsu VD; Walker L; Chiou CF; Fink JC
Clin J Am Soc Nephrol; 2010 May; 5(5):882-8. PubMed ID: 20299377
[TBL] [Abstract][Full Text] [Related]
16. The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease.
Bazeley J; Wish JB
Adv Chronic Kidney Dis; 2019 Jul; 26(4):229-236. PubMed ID: 31477253
[TBL] [Abstract][Full Text] [Related]
17. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients.
Kuwahara M; Arai Y; Takehara E; Sasaki Y; Yoshimine T; Kusaka K; Shikuma S; Akita W; Uchida S
Clin Exp Nephrol; 2016 Aug; 20(4):585-594. PubMed ID: 26511877
[TBL] [Abstract][Full Text] [Related]
18. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.
Sibbel SP; Koro CE; Brunelli SM; Cobitz AR
BMC Nephrol; 2015 Aug; 16():144. PubMed ID: 26283069
[TBL] [Abstract][Full Text] [Related]
19. The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.
Ishigami J; Onishi T; Shikuma S; Akita W; Mori Y; Asai T; Kuwahara M; Sasaki S; Tsukamoto Y
Clin Exp Nephrol; 2013 Feb; 17(1):106-14. PubMed ID: 22752396
[TBL] [Abstract][Full Text] [Related]
20. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
